Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Coccidioidomycosis: efficacy of new agents and future prospects CURRENT OPINION IN INFECTIOUS DISEASES Deresinski, S. C. 2001; 14 (6): 693-696

Abstract

Recent studies have contributed to our understanding of risk factors for severe and potentially life-threatening infections with Coccidioides immitis, allowing a more rational approach to initiation of antifungal therapy for this infection, as well as determining its intensity and duration. A large randomized trial found that itraconazole and fluconazole had similar efficacies in the treatment of progressive nonmeningeal coccidioidomycosis. An animal model of coccidioidal meningitis suggested potential efficacy of systemically administered liposomal amphotericin B. Investigational agents that have activity against C. immitis include posaconazole, voriconazole, caspofungin, and sordarin derivatives.

View details for Web of Science ID 000172663200005

View details for PubMedID 11964886